After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.

Complex products are slowly gaining a larger share of ANDA submission and approval totals, which could mean the FDA has to adapt its in-house expertise to compensate.

US FDA chief scientist said former exec, who was part of the generic drug scandal, deserves special termination of 1993 debarment due to his 'substantial assistance' to the DOJ in its investigations of others. Office of Regulatory Affairs wanted to deny his petition.